Results 1 to 10 of about 69,036 (281)

The role of gut microbiota tyrosine decarboxylases in levodopa pharmacokinetics: insights from a levodopa challenge test [PDF]

BMC Neurology
Background The gut microbiota is known to influence levodopa metabolism in the intestinal tract, primarily through the action of tyrosine decarboxylase, an enzyme encoded by the tyrosine decarboxylase gene (tyrDC). However, the effect of the abundance of
Yukun Feng, Ronggui Zhang, Guangxin Wen, Ling Xie, Tao Chen, Weiguo Liu   +5 more
doaj   +2 more sources

Levodopa-Induced Changes in Electromyographic Patterns in Patients with Advanced Parkinson’s Disease [PDF]

Frontiers in Neurology, 2018
Levodopa medication is the most efficient treatment for motor symptoms of Parkinson’s disease (PD). Levodopa significantly alleviates rigidity, rest tremor, and bradykinesia in PD.
Verneri Ruonala, Eero Pekkonen, Olavi Airaksinen, Markku Kankaanpää, Pasi A Karjalainen, Saara M Rissanen   +5 more
doaj   +4 more sources

Very-Low-Dose Levodopa Therapy for Pediatric Neurological Disorders: A Preliminary Questionnaire in Japan

Frontiers in Pediatrics, 2021
Introduction: Post-synaptic dopamine receptor supersensitivity (DARSS) has been extensively researched by Dr. Masaya Segawa, who has investigated the efficacy of very-low-dose levodopa therapy (VLDT; 0.5–1 mg/kg/day).
Kyoko Hoshino, Kyoko Hoshino, Kyoko Hoshino, Masaharu Hayashi, Masaharu Hayashi, Masaharu Hayashi, Asayo Ishizaki, Asayo Ishizaki, Kazue Kimura, Kazue Kimura, Masaya Kubota, Masaya Kubota, Atsuo Nezu, Atsuo Nezu, Akihiro Yasuhara, Akihiro Yasuhara   +15 more
doaj   +1 more source

The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program

Frontiers in Neurology, 2022
BackgroundWhile treatment with levodopa remains the cornerstone of Parkinson's disease (PD) management, chronic oral therapy is often associated with the development of motor complications, that correlate to fluctuating levodopa plasma concentrations ...
Peter A. LeWitt, Fabrizio Stocchi, David Arkadir, Yoseph Caraco, Liat Adar, Itay Perlstein, Ryan Case, Nir Giladi   +7 more
doaj   +1 more source

Levodopa responsive gait dynamics in OFF- and ONOFF-state freezing of gait in Parkinson’s disease

Clinical Parkinsonism & Related Disorders, 2023
Background: In people with Parkinson’s disease (PwPD), Freezing of Gait (FOG) episodes can be levodopa responsive (OFF-FOG) or levodopa unresponsive (ONOFF-FOG).
Tuhin Virmani, Lakshmi Pillai, Aliyah Glover, Reid D. Landes   +3 more
doaj   +1 more source

Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson's disease.

PLoS ONE, 2020
A higher levodopa dose is a strong risk factor for levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). However, levodopa dose can change during long-term medication.
Jin Yong Hong, Mun Kyung Sunwoo, Jung Han Yoon, Suk Yun Kang, Young H Sohn, Phil Hyu Lee, Seo Hyun Kim   +6 more
doaj   +1 more source

Riluzole Administration to Rats with Levodopa-Induced Dyskinesia Leads to Loss of DNA Methylation in Neuronal Genes

Cells, 2021
Dyskinesias are characterized by abnormal repetitive involuntary movements due to dysfunctional neuronal activity. Although levodopa-induced dyskinesia, characterized by tic-like abnormal involuntary movements, has no clinical treatment for Parkinson’s ...
Luca Pagliaroli, Abel Fothi, Ester Nespoli, Istvan Liko, Borbala Veto, Piroska Devay, Flora Szeri, Bastian Hengerer, Csaba Barta, Tamas Aranyi   +9 more
doaj   +1 more source

Locus Coeruleus Degeneration Correlated with Levodopa Resistance in Parkinson’s Disease: A Retrospective Analysis

Journal of Parkinson’s Disease, 2021
Background: The widely divergent responsiveness of Parkinson’s disease (PD) patients to levodopa is an important clinical issue because of its relationship with quality of life and disease prognosis.
Cheng Zhou, Tao Guo, JingJing Wu, Linbo Wang, Xueqin Bai, Ting Gao, Xiaojun Guan, Luyan Gu, Peiyu Huang, Min Xuan, Quanquan Gu, Xiaojun Xu, Baorong Zhang, Wei Cheng, Jianfeng Feng, Minming Zhang   +15 more
doaj   +1 more source

Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase

npj Parkinson's Disease, 2021
Peripheral decarboxylase inhibitors (PDIs) prevent conversion of levodopa to dopamine in the blood by the enzyme aromatic L-amino acid decarboxylase (AADC). Alterations in enzyme activity may contribute to the required higher dosages of levodopa observed
Anouke van Rumund, Lukas Pavelka, Rianne A. J. Esselink, Ben P. M. Geurtz, Ron A. Wevers, Brit Mollenhauer, Rejko Krüger, Bastiaan R. Bloem, Marcel M. Verbeek   +8 more
doaj   +1 more source

Levodopa-induced pseudopheochromocytoma

European Journal of Case Reports in Internal Medicine, 2023
Pseudopheochromocytoma is a pathological condition presenting with paroxysmal hypertension with normal or moderate elevation in catecholamines and metanephrine levels, but no evidence of a tumoural cause. Imaging studies and I-123 metaiodobenzylguanidine scintigraphy are essential for exclusion of pheocromocytoma.
Joana Bernardino Cardoso, Ana Silveira, Sara Duarte, Ruth Fortes, Ahmed Botelho, Ana Simas, Rui Suzano   +6 more
openaire   +3 more sources